Annals of Nuclear Medicine最新文献

{"title":"DOCK–PET: database of CNS kinetic parameters in the healthy human brain for existing PET tracers","authors":"Itsuki Miyajima,&nbsp;Ayano Yoshikawa,&nbsp;Kyosei Sahashi,&nbsp;Chie Seki,&nbsp;Yuji Nagai,&nbsp;Hiroshi Watabe,&nbsp;Miho Shidahara","doi":"10.1007/s12149-024-01947-z","DOIUrl":"10.1007/s12149-024-01947-z","url":null,"abstract":"<div><h3>Purpose</h3><p>Information about developed positron emission tomography (PET) tracers and obtained clinical PET images is publicly available in a database. However, findings regarding the kinetic parameters of PET tracers are yet to be summarized. Therefore, in this study, we created an open-access database of central nervous system (CNS) kinetic parameters in the healthy human brain for existing PET tracers (DOCK–PET).</p><h3>Methods</h3><p>Our database includes information on the kinetic parameters and compounds of existing CNS–PET tracers. The kinetic parameter dataset comprises the analysis methods, <i>V</i>_T, <i>BP</i>_ND, <i>K</i> parameters, relevant literature, and study details. The list of PET tracers and kinetic parameter information was compiled through keyword-based searches of PubMed and the Molecular Imaging and Contrast Agent Database (MICAD). The kinetic parameters obtained, including <i>V</i>_T, <i>BP</i>_ND, and <i>K</i> parameters, were reorganized based on the defined brain anatomical regions. All data were rigorously double-checked before being summarized in Microsoft Excel and JavaScript Object Notation (JSON) formats.</p><h3>Results</h3><p>Of the 247 PET tracers identified through searches using the PubMed and MICAD websites, the kinetic parameters of 120 PET tracers were available. Among the 120 PET tracers, compound structures with chemical and physical properties were obtained from the PubChem website or the ChemDraw software. Furthermore, the affinity information of the 104 PET tracers was gathered from PubChem or extensive literature surveys of the 120 PET tracers.</p><h3>Conclusions</h3><p>We developed a comprehensive open-access database, DOCK–PET, that includes both kinetic parameters of healthy humans and compound information for existing CNS–PET tracers.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141174392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the impact of recent COVID-19 infection on perfusion and functional parameters derived from gated myocardial perfusion imaging in patients undergoing evaluation for coronary artery disease","authors":"Maryam Alvandi,&nbsp;Zahra Shaghaghi,&nbsp;Zhino Fatehi,&nbsp;Behshad Naghshtabrizi,&nbsp;Tayeb Mohammadi,&nbsp;Safoora Nikzad","doi":"10.1007/s12149-024-01946-0","DOIUrl":"10.1007/s12149-024-01946-0","url":null,"abstract":"<div><h3>Objective</h3><p>This study seeks to evaluate how recent COVID-19 infection affects myocardial perfusion and functional parameters derived from gated myocardial perfusion imaging in patients undergoing evaluation for coronary artery disease. The goal is to enhance our understanding of COVID-19’s influence on the cardiovascular system.</p><h3>Method</h3><p>Conducted at Farshchian Heart Hospital from 2022 to 2023, this case–control study enrolled patients suspected of coronary artery disease, stratified into two groups: those with confirmed COVID-19 infection within the past 6 months (study group) and those without prior COVID-19 infection (control group). Employing a 2-day protocol, stress testing and gated SPECT MPI were performed. Statistical analysis included descriptive statistics, Chi-square test, Student’s <i>t</i> test, and Mann–Whitney <i>U</i> test.</p><h3>Result</h3><p>Among the 86 patients included, 43 were in each group. Significantly higher summed stress core and summed difference score values were observed in the study group compared to the control group (<i>p</i> &lt; 0.05). In addition, the study group exhibited significantly altered global left ventricular ejection fraction, end-diastolic volume, and end-systolic volume (<i>p</i> &lt; 0.05). Non-perfusion findings, including transient ischemic dilation and transient right ventricular visualization, were more prevalent in the study group.</p><h3>Conclusion</h3><p>Recent COVID-19 infection is associated with impaired myocardial perfusion and altered functional parameters as detected by MPI. These findings underscore the intricate interplay between COVID-19 and cardiovascular health, emphasizing the importance of comprehensive evaluation and management strategies to address cardiac complications in affected individuals. Further research is warranted to elucidate the underlying mechanisms and optimize patient care in the context of COVID-19-associated cardiovascular manifestations.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141160462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]FDG PET/CT is useful in discriminating invasive adenocarcinomas among pure ground-glass nodules: comparison with CT findings—a bicenter retrospective study","authors":"Jung Won Moon,&nbsp;Yun Hye Song,&nbsp;Yoo Na Kim,&nbsp;Ji Young Woo,&nbsp;Hye Joo Son,&nbsp;Hee Sung Hwang,&nbsp;Suk Hyun Lee","doi":"10.1007/s12149-024-01944-2","DOIUrl":"10.1007/s12149-024-01944-2","url":null,"abstract":"<div><h3>Purpose</h3><p>Predicting the malignancy of pure ground-glass nodules (GGNs) using CT is challenging. The optimal role of [¹⁸F]FDG PET/CT in this context has not been clarified. We compared the performance of [¹⁸F]FDG PET/CT in evaluating GGNs for predicting invasive adenocarcinomas (IACs) with CT.</p><h3>Methods</h3><p>From June 2012 to December 2020, we retrospectively enrolled patients with pure GGNs on CT who underwent [¹⁸F]FDG PET/CT within 90 days. Overall, 38 patients with 40 ≥ 1–cm GGNs were pathologically confirmed. CT images were analyzed for size, attenuation, uniformity, shape, margin, tumor–lung interface, and internal/surrounding characteristics. Visual [¹⁸F]FDG positivity, maximum standardized uptake value (SUV_max), and tissue fraction-corrected SUV_max (SUV_maxTF) were evaluated on PET/CT.</p><h3>Results</h3><p>The histopathology of the 40 GGNs were: 25 IACs (62.5%), 9 minimally invasive adenocarcinomas (MIA, 22.5%), and 6 adenocarcinomas in situ (AIS, 15.0%). No significant differences were found in CT findings according to histopathology, whereas visual [¹⁸F]FDG positivity, SUV_max, and SUV_maxTF were significantly different (<i>P</i>=0.001, 0.033, and 0.018, respectively). The size, visual [¹⁸F]FDG positivity, SUV_max, and SUV_maxTF showed significant diagnostic performance to predict IACs (area under the curve=0.693, 0.773, 0.717, and 0.723, respectively; <i>P</i>=0.029, 0.001, 0.018, and 0.013, respectively). In the multivariate logistic regression analysis, visual [¹⁸F]FDG positivity discriminated IACs among GGNs among various CT and PET findings (<i>P</i>=0.008).</p><h3>Conclusions</h3><p>[¹⁸F]FDG PET/CT demonstrated superior diagnostic performance compared to CT in differentiating IAC from AIS/MIA among pure GGNs, thus it has the potential to guide the proper management of patients with pure GGNs.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141096836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Booster administration of Tc-99m PMT for delayed static imaging in patients with biliary atresia","authors":"Takahiro Hosokawa,&nbsp;Mayuki Uchiyama,&nbsp;Yutaka Tanami,&nbsp;Yumiko Sato,&nbsp;Yasuharu Wakabayashi,&nbsp;Eiji Oguma","doi":"10.1007/s12149-024-01940-6","DOIUrl":"10.1007/s12149-024-01940-6","url":null,"abstract":"<div><h3>Objective</h3><p>Tc-99m <i>N</i>-pyridoxyl-5-methyl-tryptophan (PMT) hepatobiliary scintigraphy has high diagnostic performance for biliary atresia. Our hospital implements standard Tc-99m PMT administration followed by a 6 h static imaging review; booster doses are given in cases requiring 24 h delayed scans. This study aimed to evaluate the diagnostic performance of this method.</p><h3>Methods</h3><p>A total of 37 pediatric patients who underwent Tc-99m PMT biliary scintigraphy were classified into the surgically-diagnosed biliary atresia or non-biliary atresia groups. The absence of tracer accumulation in the small bowel was considered a hepatobiliary scintigraphic diagnosis of biliary atresia. The Clopper–Pearson method was used to calculate the 95% confidence intervals (CIs) for determining the diagnostic accuracy, negative predictive value, positive predictive value, sensitivity, and specificity of Tc-99m PMT biliary scintigraphy.</p><h3>Results</h3><p>Among the 37 patients, 12 were classified into the diagnosis of biliary atresia group. Regarding biliary scintigraphy findings, 16 of 37 patients demonstrated tracer accumulation in the small bowel within 6 h of testing. These cases were diagnosed as non-biliary atresia, requiring no further testing or booster administration. In contrast, 21 patients underwent delayed testing requiring booster administration, which revealed 13 without tracer excretion and 11 who were diagnosed with biliary atresia. Among the eight patients with tracer accumulation, only one was diagnosed with biliary atresia. Furthermore, two cases without tracer excretion and seven cases with tracer excretion were clinically diagnosed as non-biliary atresia. The diagnostic performance of our examination was as follows: a diagnostic accuracy of 91.9% (34/37; 95% CIs 78.0–98.3%), sensitivity of 91.6% (11/12; 95% CIs 61.5–99.8%), specificity of 92.0% (23/25; 95% CIs 74.0–99.0%), a positive predictive value of 84.6% (11/13; 95% CIs 54.6–98.0%), and a negative predictive value of 95.8% (23/24; 95% CIs 78.9–99.9%).</p><h3>Conclusions</h3><p>Our protocol for Tc-99m PMT biliary scintigraphy using tracer booster administration demonstrated reliable diagnostic performance for biliary atresia. Notably, 43% of cases did not require booster administration, indicating that lesser radiation exposure may still yield comparable diagnostic accuracy.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141096838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between the thyroid computed tomography value and thyroid function in hyperthyroidism: a retrospective study","authors":"Haruna Iwanaga,&nbsp;Naotoshi Fujita,&nbsp;Shinji Abe,&nbsp;Shinji Naganawa,&nbsp;Katsuhiko Kato","doi":"10.1007/s12149-024-01938-0","DOIUrl":"10.1007/s12149-024-01938-0","url":null,"abstract":"<div><h3>Objective</h3><p>Radioiodine (I-131) therapy for hyperthyroidism is a well-established and safe treatment option. This study aimed to investigate the relationship between the computed tomography (CT) value and the function and volume of the thyroid gland by identifying the factors that induce changes in the CT value of patients with hyperthyroidism.</p><h3>Methods</h3><p>This retrospective study evaluated 38 patients with Graves’ disease and 10 patients with Plummer disease. To obtain the mean CT value and volume of the thyroid gland, the entire thyroid gland was set as the region of interest. A test dose of 3.7 MBq I-131 was administered before initiating I-131 therapy, and the radioiodine uptake (RIU) rate was assessed after 3, 24, 96, and 168 h. An approximate curve was plotted based on the RIU values obtained, and the effective half-life (EHL) was calculated. The correlation between the mean CT value and the volume of the thyroid gland, 24-h RIU, EHL, and the free triiodothyronine (FT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and TSH receptor antibody (TRAb) levels was evaluated.</p><h3>Results</h3><p>The CT value exhibited a significant positive correlation with EHL in patients with Graves’ disease (r = 0.62, <i>p</i> &lt; 0.0001) as well as patients with Plummer disease (r = 0.74, <i>p</i> &lt; 0.05). However, it did not display any correlation with the remaining parameters.</p><h3>Conclusion</h3><p>The CT value is significantly correlated with EHL, suggesting that it reflects thyroid function and is mainly related to the factors associated with iodine discharge.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11282127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141086402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual-time-point dynamic 68Ga-PSMA-11 PET/CT for parametric imaging generation in prostate cancer","authors":"Paphawarin Burasothikul,&nbsp;Chatchai Navikhacheevin,&nbsp;Panya Pasawang,&nbsp;Tanawat Sontrapornpol,&nbsp;Chanan Sukprakun,&nbsp;Kitiwat Khamwan","doi":"10.1007/s12149-024-01939-z","DOIUrl":"10.1007/s12149-024-01939-z","url":null,"abstract":"<div><h3>Purpose</h3><p>To investigate the optimal dual-time-point (DTP) approaches using dynamic ^<b>68</b>Ga-PSMA-11 PET/CT imaging to generate parametric images for prostate cancer patients.</p><h3>Methods</h3><p>Fifteen patients with prostate cancer were intravenously administered ⁶⁸Ga-PSMA-11 of 181.9 ± 47.2 MBq, followed by an immediate 60 min dynamic PET/CT scan. List-mode data were reconstructed into 25 timeframes (6 × 10 s, 8 × 30 s, and 11 × 300 s) and corrected for motion and partial volume effect. DTP parametric images were generated using different interval time points of 5 min and 10 min, with a minimum of 30 min time interval. Net influx rates (<i>K</i>_i) were calculated through the fitting of a single irreversible two-tissue compartmental model. Intraclass correlation coefficient (ICC) values between DTP protocols and 60 min <i>K</i>_i were obtained. Lesion-to-background ratios (LBRs) of <i>K</i>_i and standardized uptake value (SUV) images in each DTP protocol were determined.</p><h3>Results</h3><p>The DTP protocol of 5–10 min with a 40–45 min interval showed the highest ICC of 0.988 compared with the 60 min <i>K</i>_i, whereas the ICC values for the intervals of 0–5 min with 55–60 min and 0–10 min with 50–60 min were 0.941. The LBRs of the 60 min <i>K</i>_i, 5–10 min with 40–45 min <i>K</i>_i, 0–5 min with 55–60 min <i>K</i>_i, 0–10 min with 50–60 min <i>K</i>_i, SUV_mean, and SUV_max images were 29.53 ± 27.33, 13.05 ± 15.28, 45.15 ± 53.11, 45.52 ± 70.31, 19.77 ± 23.43, and 25.06 ± 30.07, respectively.</p><h3>Conclusion</h3><p>The 0–5 min with 55–60 min DTP parametric imaging exhibits a comparable <i>K</i>_i to 60 min parametric imaging and remarkable image quality and contrast than SUV imaging, enhancing prostate cancer diagnosis while maintaining time efficiency.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140955865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of hormone therapy on physiological uptake of the endometrium on [18F]F-FDG PET in postmenopausal women","authors":"Ryusuke Nakamoto,&nbsp;Masahiro Yakami,&nbsp;Tomomi W. Nobashi,&nbsp;Hiroyoshi Isoda,&nbsp;Yuji Nakamoto","doi":"10.1007/s12149-024-01941-5","DOIUrl":"10.1007/s12149-024-01941-5","url":null,"abstract":"<div><h3>Objective</h3><p>The effects of hormonal therapy, estrogen-based hormone replacement therapy (HRT), and anti-tumor hormone therapy, such as tamoxifen, on the physiological uptake of the endometrium on 2-deoxy-2[¹⁸F]fluoro-<span>d</span>-glucose ([¹⁸F]F-FDG) positron emission tomography (PET) in postmenopausal women have not been determined. We explored the effect of hormone therapy, particularly HRT, on physiological uptake in the endometrium of postmenopausal women.</p><h3>Materials and methods</h3><p>Postmenopausal women receiving hormone therapy who underwent cancer screening using PET/computed tomography (CT) between June 2016 and April 2023 were included in the hormone therapy group (<i>n</i> = 21). Postmenopausal women with no history of hormone therapy were included in the control group (<i>n</i> = 49). First, the physiological endometrial uptake at menopausal age and at least 1 year thereafter was compared quantitatively (SUVmax) and qualitatively (4-point scale) in the control group, to assess when the endometrium ceased to show significant physiological [¹⁸F]F-FDG uptake after menopause. Endometrial uptake was compared between the hormone therapy and control groups. The association between HRT duration (months) and endometrial uptake (SUVmax) was evaluated. Endometrial thickness, measured using transvaginal ultrasonography, was also compared between the two groups.</p><h3>Results</h3><p>Endometrial uptake was significantly reduced both qualitatively and quantitatively (<i>P</i> &lt; 0.05) at least 1 year after menopause in control patients, by which time most women (89.8%) no longer had significant endometrial uptake. The hormone therapy group (<i>n</i> = 21) showed higher FDG uptake in the endometrium compared to the control group (median SUVmax: 2.3 vs 1.9, <i>P</i> = 0.0011), as well as a higher visual score (<i>P</i> &lt; 0.0001). HRT duration did not correlate with endometrial uptake (<i>P</i> = 0.097). Endometrial thickness in the hormone therapy group was significantly thicker than in the control group (median: 3.9 mm vs 1.8 mm, <i>P</i> = 0.002).</p><h3>Conclusion</h3><p>Hormone therapy may affect physiological uptake in the endometrium in postmenopausal women.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140955801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of 68Ga-PSMA-11 PET/CT: a Phase 1 clinical study in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer","authors":"Anri Inaki,&nbsp;Atsushi Mizokami,&nbsp;Hiroshi Wakabayashi,&nbsp;Kouji Izumi,&nbsp;Yoshifumi Kadono,&nbsp;Tadashi Toyama,&nbsp;Shizuko Takahara,&nbsp;Toshinori Murayama,&nbsp;Seigo Kinuya","doi":"10.1007/s12149-024-01931-7","DOIUrl":"10.1007/s12149-024-01931-7","url":null,"abstract":"<div><h3>Background</h3><p>Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals allow whole-body imaging to detect prostate cancer (PC). Positron emission tomography imaging using gallium-68 (⁶⁸Ga)-PSMA-11 has been shown to have a favorable safety and tolerability profile and high diagnostic performance. The study evaluates the safety and pharmacokinetics of ⁶⁸Ga-PSMA-11 in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer.</p><h3>Methods</h3><p>This single arm study enrolled Japanese patients with primary PC (<i>n</i> = 3), suspected recurrent PC following radical prostatectomy (<i>n</i> = 4), or suspected recurrent PC following radical radiotherapy (<i>n</i> = 3). All patients received a single intravenous dose of ⁶⁸Ga-PSMA-11 2.0 MBq/kg (±10%) followed by PSMA PET imaging and safety and pharmacokinetic evaluations. Based on the blood concentrations of ⁶⁸Ga-PSMA-11 and the radioactivity distribution rate in each organ/tissue, the absorbed doses in major organs/tissues and the whole-body effective dose were calculated by the Medical Internal Radiation Dose method.</p><h3>Results</h3><p>Ten patients were enrolled. Mean age was 73.3 ± 4.8 years, and median prostate-specific antigen was 8.250 ng/mL. Five patients (50%) experienced a total of 6 adverse events, and no grade ≥ 2 adverse events or serious adverse events were reported. No clinically significant changes in vital signs, haematology parameters, or blood chemistry or ECG abnormalities were observed. The estimated whole body effective dose of ⁶⁸Ga-PSMA-11 (mean ± standard deviation) was 2.524 × 10^–2 ± 2.546 × 10^–3 mSv/MBq. Time to maximum concentration (1.16 × 10^–4 ± 1.3 × 10^–5% ID/mL) in whole blood was 2.15 ± 0.33 min.</p><h3>Conclusions</h3><p>⁶⁸Ga-PSMA-11 has a favourable safety and tolerability profile in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer, which is comparable to previous observations in other populations.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11281955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140943882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of F-18 FDG PET/CT in differentiating autoimmune pancreatitis from pancreatic cancer: a systemic review and meta-analysis","authors":"Deepanksha Datta,&nbsp;B. Selvakumar,&nbsp;Akhil Dhanesh Goel,&nbsp;Sanskriti Chhibber,&nbsp;Vaibhav Kumar Varshney,&nbsp;Rajesh Kumar","doi":"10.1007/s12149-024-01934-4","DOIUrl":"10.1007/s12149-024-01934-4","url":null,"abstract":"<div><h3>Objectives</h3><p>This study aims to evaluate the utility of F-18 FDG PET/CT in the non-invasive diagnosis of autoimmune pancreatitis (AIP) and differentiating it from pancreatic cancer (CaP) based on the amount and pattern of FDG uptake, as well as involvement of extra-pancreatic sites.</p><h3>Methods</h3><p>A systematic search was conducted using PubMed, Scopus, Cochrane Library and Google Scholar. Only those studies that compared the findings of F-18 FDG PET/CT in terms of SUVmax, pattern of FDG uptake and presence of FDG-avid extra-pancreatic sites in both AIP and CaP were included. Studies were qualitatively assessed for risk of bias and publication bias. The diagnostic performance of parameters on PET/CT was examined through pooled sensitivity, specificity, diagnostic odd’s ratio (DOR) and summary receiver operator characteristic (SROC) curve analysis.</p><h3>Results</h3><p>Six studies were included with a total of 580 patients. 178 patients had AIP (Age 18–90 years, male, M: female, F ratio—8.4:1) and 402 patients had CaP (Age 22–88 years, M:F ratio-1.5:1). Type of AIP was reported in only 3 studies, with the included cases predominantly being type 1 AIP. All studies were retrospective with heterogeneity and a risk on patient selection and index test. The FDG uptake, expressed as SUVmax, was lower in AIP with a weighted mean difference of −3.11 (95% confidence interval, CI: −5.28 to −0.94). To diagnose AIP, the pooled sensitivity, specificity and DOR of diffuse pattern of FDG uptake were 0.59 (95% CI: 0.51–0.66), 0.89 (95% CI: 0.86–0.92) and 21.07 (95% CI: 5.07–88.32), respectively, with an area under curve (AUC) of 0.717 on SROC analysis. The pooled sensitivity, specificity and DOR of FDG-avid extra pancreatic sites were 0.55 (95% CI: 0.45–0.65), 0.58 (95% CI: 0.52–0.64) and 2.33 (95% CI: 1.40–3.89), respectively, with an AUC of 0.632.</p><h3>Conclusion</h3><p>On F-18 FDG PET/CT, a pancreatic lesion of AIP has a lower SUVmax value than CaP. A diffuse pattern of FDG uptake and presence of an extra-pancreatic FDG-avid site are nearly 21 times and twice more likely in AIP than CaP, respectively.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140943880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value of lymph node to primary tumor standardized uptake value ratio in cancer patients: a meta-analysis","authors":"Wing-Keen Yap,&nbsp;Ken-Hao Hsu,&nbsp;Ting-Hao Wang,&nbsp;Chia-Hsin Lin,&nbsp;Chung-Jan Kang,&nbsp;Shih-Ming Huang,&nbsp;Huan-Chun Lin,&nbsp;Tsung-Min Hung,&nbsp;Kai-Ping Chang,&nbsp;Tsung-You Tsai","doi":"10.1007/s12149-024-01933-5","DOIUrl":"10.1007/s12149-024-01933-5","url":null,"abstract":"<div><h3>Objective</h3><p>The lymph node to primary tumor standardized uptake value ratio (NTR) is an innovative parameter derived from positron emission tomography/computed tomography (PET/CT) scans that captures the intricate relationship between primary tumors and associated lymph nodes. This meta-analysis aimed to investigate the prognostic value of NTR in cancer patients.</p><h3>Methods</h3><p>A systematic search of PubMed, Cochrane, and Embase databases was conducted to identify studies investigating the association between NTR and survival outcomes in cancer patients. The pooled adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) were calculated using a random-effects model.</p><h3>Results</h3><p>Twelve studies comprising a total of 2037 patients were included in the meta-analysis. Elevated NTR was significantly associated with worse overall survival aHR (2.21, 95% CI 1.63 to 2.99), disease-free survival aHR (3.27, 95% CI 2.12 to 5.05), and distant metastasis-free survival aHR (2.07, 95% CI 1.55 to 2.78) in cancer patients. Subgroup analyses by cancer type showed consistent results across various malignancies, including head and neck squamous cell carcinoma, endometrial carcinoma, lung cancer, breast cancer, and nasopharyngeal carcinoma.</p><h3>Conclusions</h3><p>This meta-analysis provides evidence for a significant association between elevated NTR and worse survival outcomes in cancer patients. Elevated NTR may serve as a useful prognostic biomarker for cancer patients and could potentially be used to guide treatment decisions and monitor disease progression. Future studies should aim to validate these findings in larger and more diverse patient populations and investigate the underlying mechanisms for the observed association between NTR and survival outcomes.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140896890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}